Verona signs China deal for PhIII COPD drug; Teva continues legal battle with Eli Lilly, alleging new patent infringements on migraine drug
After a February Phase II win put Verona’s bad memories of a 2019 flop behind them, the company is now engaging in partnerships to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.